uniQure (QURE)
uniQure on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
8.7M
Short interest
settlement 2026-09-30
1.9
Days to cover
-6.2 days vs prior
44.4%
Short share of volume
2026-10-09
52,675
Fails to deliver
settlement 2026-09-10
Mon 9 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in QURE is 8,715,837 shares, down 1,158,580 shares over the last month. Over the last 48 readings it ranged from 2,439,803 shares (14 February 2025) to 12,718,685 shares (13 March 2026). At the reported average volume of 4.5M shares a day that is 1.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/qure" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 8,715,837 | -12.1% | 4,488,701 | 1.94 |
| 2026-09-15 | 9,920,512 | +0.5% | 1,218,918 | 8.14 |
| 2026-08-31 | 9,874,417 | -8.3% | 1,048,356 | 9.42 |
| 2026-08-14 | 10,770,406 | +0.8% | 1,094,064 | 9.84 |
| 2026-07-31 | 10,683,529 | +3.0% | 1,572,428 | 6.79 |
| 2026-07-15 | 10,367,823 | -9.8% | 1,456,856 | 7.12 |
| 2026-06-30 | 11,494,705 | -2.6% | 4,466,160 | 2.57 |
| 2026-06-15 | 11,805,442 | +6.3% | 1,440,727 | 8.19 |
| 2026-05-29 | 11,100,357 | +7.8% | 1,228,078 | 9.04 |
| 2026-05-15 | 10,298,060 | -4.5% | 2,565,817 | 4.01 |
| 2026-04-30 | 10,784,518 | -2.8% | 1,533,215 | 7.03 |
| 2026-04-15 | 11,097,615 | +1.1% | 1,500,297 | 7.40 |
| 2026-03-31 | 10,981,448 | -13.7% | 1,985,368 | 5.53 |
| 2026-03-13 | 12,718,685 | +0.8% | 8,127,981 | 1.56 |
| 2026-02-27 | 12,617,484 | +17.6% | 3,807,566 | 3.31 |
| 2026-02-13 | 10,727,684 | -5.9% | 2,069,859 | 5.18 |
| 2026-01-30 | 11,396,509 | -1.5% | 1,721,848 | 6.62 |
| 2026-01-15 | 11,569,838 | -3.6% | 1,969,383 | 5.87 |
| 2025-12-31 | 11,996,689 | +33.8% | 2,755,072 | 4.35 |
| 2025-12-15 | 8,966,485 | +7.6% | 2,943,760 | 3.05 |
| 2025-11-28 | 8,335,603 | -0.7% | 1,907,330 | 4.37 |
| 2025-11-14 | 8,390,666 | +21.6% | 7,377,153 | 1.14 |
| 2025-10-31 | 6,901,368 | -8.9% | 1,731,878 | 3.98 |
| 2025-10-15 | 7,573,225 | -31.4% | 3,195,780 | 2.37 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of QURE volume is 44.4%, up 20.5 points over the last five sessions. Over the last 30 readings it ranged from 21.2% (31 August 2026) to 47.4% (8 September 2026). The latest reading is 10.4 points above the 30-session average of 34.1%, on 339K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 151K | 339K | 44.4% | 0 |
| 2026-10-08 | 243K | 780K | 31.2% | 0 |
| 2026-10-07 | 184K | 520K | 35.4% | 0 |
| 2026-10-06 | 423K | 1.1M | 37.1% | 632 |
| 2026-10-05 | 392K | 1.2M | 31.6% | 400 |
| 2026-10-02 | 199K | 831K | 24.0% | 13,310 |
| 2026-10-01 | 260K | 945K | 27.5% | 1,757 |
| 2026-09-30 | 844K | 2.5M | 33.2% | 50,604 |
| 2026-09-29 | 2.4M | 9.0M | 27.0% | 229,901 |
| 2026-09-28 | 195K | 587K | 33.2% | 50 |
| 2026-09-25 | 165K | 546K | 30.3% | 28,182 |
| 2026-09-24 | 722K | 2.2M | 33.4% | 52,052 |
| 2026-09-23 | 173K | 426K | 40.8% | 335 |
| 2026-09-22 | 134K | 477K | 28.2% | 100 |
| 2026-09-21 | 154K | 346K | 44.5% | 11,277 |
| 2026-09-18 | 118K | 518K | 22.8% | 0 |
| 2026-09-17 | 81K | 235K | 34.4% | 0 |
| 2026-09-16 | 161K | 598K | 26.9% | 0 |
| 2026-09-15 | 217K | 545K | 39.8% | 0 |
| 2026-09-14 | 92K | 234K | 39.4% | 0 |
| 2026-09-11 | 247K | 536K | 46.1% | 0 |
| 2026-09-10 | 99K | 362K | 27.4% | 219 |
| 2026-09-09 | 168K | 546K | 30.7% | 0 |
| 2026-09-08 | 294K | 619K | 47.4% | 0 |
| 2026-09-04 | 159K | 415K | 38.2% | 3,481 |
| 2026-09-03 | 243K | 606K | 40.0% | 7,671 |
| 2026-09-02 | 382K | 1.0M | 37.1% | 600 |
| 2026-09-01 | 83K | 239K | 34.6% | 33 |
| 2026-08-31 | 108K | 507K | 21.2% | 1 |
| 2026-08-28 | 108K | 314K | 34.2% | 100 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 10 September 2026, the fails-to-deliver balance in QURE is 52,675 shares, up 52,638 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (13 July 2026) to 120,547 shares (26 June 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-10 | 52,675 | $46.00 | $2.4M |
| 2026-09-02 | 37 | $47.86 | $2K |
| 2026-08-31 | 20 | $48.72 | $974 |
| 2026-08-25 | 30 | $47.46 | $1K |
| 2026-08-21 | 52 | $48.89 | $3K |
| 2026-08-19 | 587 | $47.38 | $28K |
| 2026-08-17 | 38 | $48.62 | $2K |
| 2026-08-13 | 2,763 | $45.13 | $125K |
| 2026-08-11 | 52 | $46.06 | $2K |
| 2026-08-07 | 2,533 | $45.36 | $115K |
| 2026-08-06 | 7 | $44.24 | $310 |
| 2026-07-27 | 19,009 | $38.97 | $741K |
| 2026-07-23 | 3,688 | $40.38 | $149K |
| 2026-07-13 | 2 | $42.63 | $85 |
| 2026-07-08 | 31,982 | $41.41 | $1.3M |
| 2026-07-07 | 162 | $41.36 | $7K |
| 2026-06-29 | 41,941 | $47.51 | $2.0M |
| 2026-06-26 | 120,547 | $49.10 | $5.9M |
| 2026-06-25 | 24,474 | $48.85 | $1.2M |
| 2026-06-24 | 1,274 | $49.04 | $62K |
| 2026-06-22 | 1,214 | $46.29 | $56K |
| 2026-06-18 | 24,128 | $48.16 | $1.2M |
| 2026-06-17 | 1,950 | $26.99 | $53K |
| 2026-06-16 | 1,011 | $27.87 | $28K |
| 2026-06-15 | 4 | $27.57 | $110 |
| 2026-06-10 | 3,283 | $26.46 | $87K |
| 2026-06-09 | 1,071 | $27.00 | $29K |
| 2026-06-08 | 18,263 | $26.45 | $483K |
| 2026-06-02 | 124 | $28.22 | $3K |
| 2026-05-29 | 5,599 | $24.85 | $139K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for QURE in the last 90 days. The most recent filings are listed below. Latest filing: Kapusta Matthew C (CEO, Managing Director) on 2026-07-02.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | Kapusta Matthew C | CEO, Managing Director | Sell | 8K | $45.89 | $349K | 519K |
| 2026-07-02 | Kapusta Matthew C | CEO, Managing Director | Sell | 4K | $45.43 | $195K | 527K |
| 2026-07-02 | Kapusta Matthew C | CEO, Managing Director | Sell | 9K | $44.43 | $409K | 531K |
| 2026-07-02 | Kapusta Matthew C | CEO, Managing Director | Option exercise | 21K | $19.39 | $409K | 540K |
| 2026-06-30 | Kaye Jack | Director | Sell | 17K | $46.43 | $792K | 26K |
| 2026-06-30 | Kaye Jack | Director | Option exercise | 17K | $20.18 | $344K | 43K |
| 2026-06-30 | Kaye Jack | Director | Sell | 4K | $46.49 | $191K | 26K |
| 2026-06-30 | Kaye Jack | Director | Option exercise | 4K | $37.00 | $152K | 30K |
| 2026-06-30 | Abi-Saab Walid | Chief Medical Officer | Sell | 20K | $46.40 | $928K | 148K |
| 2026-06-30 | Abi-Saab Walid | Chief Medical Officer | Sell | 10K | $46.46 | $465K | 168K |
| 2026-06-30 | Abi-Saab Walid | Chief Medical Officer | Option exercise | 10K | $5.59 | $56K | 178K |
| 2026-06-26 | Abi-Saab Walid | Chief Medical Officer | Sell | 1K | $46.86 | $67K | 168K |
| 2026-06-25 | Kapusta Matthew C | CEO, Managing Director | Sell | 29K | $50.02 | $1.4M | 519K |
| 2026-06-25 | Kapusta Matthew C | CEO, Managing Director | Option exercise | 29K | $31.71 | $911K | 548K |
| 2026-06-24 | Kapusta Matthew C | CEO, Managing Director | Option exercise | 4K | $31.71 | $131K | 526K |
| 2026-06-24 | Kapusta Matthew C | CEO, Managing Director | Sell | 7K | $50.00 | $335K | 519K |
| 2026-06-18 | Kapusta Matthew C | CEO, Managing Director | Option exercise | 5K | $31.71 | $148K | 563K |
| 2026-06-18 | Kapusta Matthew C | CEO, Managing Director | Sell | 5K | $50.00 | $233K | 559K |
| 2026-06-18 | Kapusta Matthew C | CEO, Managing Director | Sell | 37K | $50.00 | $1.9M | 522K |
| 2026-06-17 | Kaye Jack | Director | Sell | 5K | $42.57 | $225K | 26K |
| 2026-06-17 | Kaye Jack | Director | Option exercise | 5K | $31.71 | $168K | 31K |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Sell | 57K | $43.43 | $2.5M | 604K |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Sell | 6K | $43.70 | $263K | 693K |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Sell | 24K | $42.61 | $1.0M | 699K |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Option exercise | 63K | $19.39 | $1.2M | 723K |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Sell | 33K | $45.01 | $1.5M | 570K |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Sell | 12K | $48.65 | $564K | 559K |
| 2026-06-17 | Kapusta Matthew C | CEO, Managing Director | Sell | 33K | $45.02 | $1.5M | 661K |
| 2026-06-17 | Balachandran Madhavan | Director | Sell | 2K | $42.60 | $72K | 43K |
| 2026-06-17 | Balachandran Madhavan | Director | Sell | 5K | $43.66 | $205K | 45K |
| 2026-06-17 | Balachandran Madhavan | Director | Sell | 5K | $47.08 | $249K | 50K |
| 2026-06-17 | Balachandran Madhavan | Director | Option exercise | 6K | $19.39 | $124K | 55K |
| 2026-06-17 | Balachandran Madhavan | Director | Option exercise | 5K | $31.71 | $168K | 49K |
| 2026-06-15 | Potts Jeannette | Chief Legal Officer | Sell | 5K | $27.67 | $145K | 133K |
| 2026-06-15 | Balachandran Madhavan | Director | Option exercise | 10K | $8.49 | $85K | 53K |
| 2026-06-15 | Balachandran Madhavan | Director | Sell | 10K | $27.85 | $279K | 43K |
| 2026-06-11 | Balachandran Madhavan | Director | Sell | 2K | $27.06 | $54K | 43K |
| 2026-06-11 | Jacques Rachelle Suzanne | Director | Sell | 2K | $27.06 | $54K | 34K |
| 2026-06-11 | Kaye Jack | Director | Sell | 2K | $27.06 | $54K | 26K |
| 2026-06-11 | POST LEONARD E | Director | Sell | 2K | $27.06 | $54K | 35K |
| 2026-06-11 | Springhorn Jeremy P. | Director | Sell | 2K | $27.06 | $54K | 43K |
| 2026-06-11 | O'Keefe Kylie | Chief Customer & Strat Officer | Sell | 16K | $27.06 | $431K | 109K |
| 2026-06-11 | Gut Robert | Director | Sell | 3K | $27.06 | $74K | 32K |
| 2026-06-11 | Meek David D. | Director | Sell | 2K | $27.06 | $54K | 40K |
| 2026-06-10 | Balachandran Madhavan | Director | Grant | 8K | $0.00 | $0 | 45K |
| 2026-06-10 | Jacques Rachelle Suzanne | Director | Grant | 8K | $0.00 | $0 | 36K |
| 2026-06-10 | Kaye Jack | Director | Grant | 8K | $0.00 | $0 | 28K |
| 2026-06-10 | POST LEONARD E | Director | Grant | 8K | $0.00 | $0 | 37K |
| 2026-06-10 | Springhorn Jeremy P. | Director | Grant | 8K | $0.00 | $0 | 45K |
| 2026-06-10 | Gut Robert | Director | Grant | 8K | $0.00 | $0 | 35K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON37 Form 144 notices on file for QURE worth $32.2M at the prices reported; 0 in the last 90 days worth $0. Latest: Kapusta Matthew C filed on 2026-07-02 to sell 21,082 shares ($952K) from 2026-07-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-07-02 | Kapusta Matthew COfficer, Director, CEO AND MANAGING DIRECTOR | 21K | $952K | 0.033% | 2026-07-02 | CITIGROUP GLOBAL MARKETS |
| 2026-06-30 | Kaye JackDirector | 21K | $983K | 0.034% | 2026-06-30 | Citigroup Global Markets, Inc |
| 2026-06-30 | Abi-Saab WalidChief Medical Officer | 30K | $1.4M | 0.048% | 2026-06-30 | Citigroup Global Markets, Inc |
| 2026-06-26 | Abi-Saab WalidChief Medical Officer | 1K | $67K | 0.002% | 2026-06-26 | Citigroup Global Markets, Inc |
| 2026-06-25 | Kapusta Matthew COfficer, Director, CEO AND MANAGING DIRECTOR | 29K | $1.4M | 0.046% | 2026-06-25 | CITIGROUP GLOBAL MARKETS |
| 2026-06-24 | Kapusta Matthew COfficer, Director, CEO AND MANAGING DIRECTOR | 7K | $335K | 0.011% | 2026-06-24 | CITIGROUP GLOBAL MARKETS |
| 2026-06-18 | Kapusta Matthew COfficer, Director, CEO AND MANAGING DIRECTOR | 42K | $1.9M | 0.066% | 2026-06-18 | CITIGROUP GLOBAL MARKETS |
| 2026-06-17 | Kaye JackDirector | 5K | $225K | 0.008% | 2026-06-17 | Citigroup Global Markets, Inc |
| 2026-06-17 | Kapusta Matthew COfficer, Director, CEO AND MANAGING DIRECTOR | 164K | $7.1M | 0.261% | 2026-06-17 | CITIGROUP GLOBAL MARKETS |
| 2026-06-17 | Balachandran MadhavanDirector | 12K | $526K | 0.019% | 2026-06-17 | Citigroup Global Markets, Inc |
| 2026-06-15 | Potts JeannetteOfficer, CHIEF LEGAL OFFICER | 5K | $145K | 0.008% | 2026-06-15 | CITIGROUP GLOBAL MARKETS |
| 2026-06-11 | Springhorn Jeremy P.Director | 2K | $54K | 0.003% | 2026-06-11 | Citigroup Global Markets, Inc |
| 2026-06-11 | POST LEONARD EDirector | 2K | $54K | 0.003% | 2026-06-11 | Citigroup Global Markets, Inc |
| 2026-06-11 | O'Keefe KylieOfficer, Chief Customer and Strategy Officer | 16K | $431K | 0.025% | 2026-06-11 | CITIGROUP GLOBAL MARKETS |
| 2026-06-11 | Meek David D.Director | 2K | $54K | 0.003% | 2026-06-11 | Citigroup Global Markets, Inc |
| 2026-06-11 | Kaye JackDirector | 2K | $54K | 0.003% | 2026-06-11 | Citigroup Global Markets, Inc |
| 2026-06-11 | Jacques Rachelle SuzanneDirector | 2K | $54K | 0.003% | 2026-06-11 | Citigroup Global Markets, Inc |
| 2026-06-11 | Gut RobertDirector | 3K | $74K | 0.004% | 2026-06-11 | Citigroup Global Markets, Inc |
| 2026-06-11 | Balachandran MadhavanDirector | 12K | $325K | 0.019% | 2026-06-11 | Citigroup Global Markets, Inc |
| 2026-06-10 | Gut RobertDirector | 8K | $197K | 0.012% | 2026-06-10 | Citigroup Global Markets, Inc |
| 2026-06-03 | Kaye JackDirector | 3K | $79K | 0.004% | 2026-06-03 | Citigroup Global Markets, Inc. |
| 2026-05-08 | Abi-Saab WalidChief Medical Officer | 45K | $1.1M | 0.071% | 2026-05-08 | Citigroup Global Markets, Inc |
| 2026-03-04 | Potts JeannetteOfficer, CHIEF LEGAL AND COMPLIANCE OFFICER | 3K | $31K | 0.005% | 2026-03-04 | CITIGROUP GLOBAL MARKETS |
| 2026-03-04 | Kapusta Matthew CDirector | 15K | $132K | 0.023% | 2026-03-04 | CITIGROUP GLOBAL MARKETS |
| 2026-03-04 | KLEMT CHRISTIANOfficer, CFO | 12K | $109K | 0.019% | 2026-03-04 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | Potts JeannetteOfficer, CHIEF LEGAL AND COMPLIANCE OFFICER | 9K | $85K | 0.014% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | Kapusta Matthew CDirector | 34K | $343K | 0.055% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | KLEMT CHRISTIANOfficer, CFO | 13K | $128K | 0.021% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-02-25 | Kapusta Matthew CDirector | 12K | $295K | 0.020% | 2026-02-25 | CITIGROUP GLOBAL MARKETS |
| 2026-02-25 | KLEMT CHRISTIANOfficer, CFO | 6K | $148K | 0.010% | 2026-02-25 | CITIGROUP GLOBAL MARKETS |
| 2026-01-12 | Gut RobertDirector | 26K | $677K | 0.041% | 2026-01-12 | Citigroup Global Markets, Inc |
| 2026-01-09 | Kaye JackDirector | 6K | $174K | 0.010% | 2026-01-09 | Citigroup Global Markets, Inc |
| 2025-11-06 | Gut RobertDirector | 31K | $819K | 0.051% | 2025-11-06 | CITIGROUP GLOBAL MARKETS |
| 2025-11-04 | Kaye JackDirector | 39K | $1.3M | 0.063% | 2025-11-04 | CITIGROUP GLOBAL MARKETS |
| 2025-09-26 | KLEMT CHRISTIANOfficer, CFO | 15K | $825K | 0.027% | 2025-09-26 | CITIGROUP GLOBAL MARKETS |
| 2025-09-24 | Kapusta Matthew CDirector | 226K | $9.4M | 0.412% | 2025-09-24 | CITIGROUP GLOBAL MARKETS |
| 2025-09-24 | KLEMT CHRISTIANOfficer, CFO | 3K | $120K | 0.005% | 2025-09-24 | CITIGROUP GLOBAL MARKETS |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of QURE in their latest filing, all on Schedule 13G (passive). The largest reported stake is Avoro Capital Advisors LLC at 9.9% of the class (6,150,000 shares), filed 2026-02-17 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G | RTW Investments, LPinvestment adviser, partnership | 3.9M | 5.7% | 2026-06-30 |
| 2026-08-14 | 13G | Roderick Wongparent holding company, individual | 3.9M | 5.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | G1 Execution Services, LLCbroker-dealer, other entity | 3.3M | 4.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | SIG Brokerage, LPbroker-dealer, partnership | 3.3M | 4.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Susquehanna Fundamental Investments, LLCother entity | 3.3M | 4.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Susquehanna Portfolio Strategies, LLCother entity | 3.3M | 4.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Susquehanna Securities, LLCbroker-dealer, other entity | 3.3M | 4.8% | 2026-06-30 |
| 2026-07-20 | 13G/Ano. 4 | Aberdeen Group plcparent holding company | 2.8M | 4.5% | 2026-06-30 |
| 2026-07-20 | 13G/Ano. 4 | abrdn Inc.corporation, investment adviser | 2.8M | 4.5% | 2026-06-30 |
| 2026-07-16 | 13G | JPMORGAN CHASE & COparent holding company | 4.9M | 7.0% | 2026-06-30 |
| 2026-05-12 | 13G | STATE STREET CORPORATIONparent holding company | 2.3M | 3.6% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 1 | FMR LLCparent holding company | 1.7M | 2.8% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 1.7M | 2.8% | 2026-03-31 |
| 2026-02-17 | 13G/Ano. 1 | Oleg Nodelmanparent holding company, individual | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | EcoR1 Capital Fund Qualified, L.P.partnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | EcoR1 Capital, LLCinvestment adviser, other entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Avoro Capital Advisors LLCinvestment adviser, other entity | 6.2M | 9.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Behzad Aghazadehparent holding company, individual | 6.2M | 9.9% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 5 | Vestal Point Capital, LPinvestment adviser, partnership | 225K | 0.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 5 | Ryan Wilderparent holding company, individual | 225K | 0.4% | 2025-09-30 |
13F holders
Tracked managers holding QURE at their latest 13F. JSON6 of the 30 tracked managers held QURE at their latest 13F, $164.5M in total at quarter-end prices. Two Sigma Investments is the largest at $67.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 1.5M | $67.3M | 0.05% | -1.2M |
| Citadel Advisors | 2026-06-30 | 910K | $41.9M | 0.00% | +506K |
| Point72 Asset Management | 2026-06-30 | 606K | $27.9M | 0.03% | new |
| Millennium Management | 2026-06-30 | 343K | $15.8M | 0.01% | -450K |
| D. E. Shaw & Co. | 2026-06-30 | 208K | $9.6M | 0.00% | +47K |
| AQR Capital Management | 2026-06-30 | 43K | $2.0M | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q1 FY 2026 (quarter ended 2026-03-31) uniQure reported revenue of $3.6M, up 127.3% from the same quarter a year earlier, and net loss of $53.5M (-0.85 diluted EPS). In FY 2025 it generated -$178.0M of operating cash flow. As of 2026-03-31, cash was $140.0M against $49.9M of debt.
- Cash
- $140.0M
- Debt
- $49.9M
- Equity
- $149.3M
- Total assets
- $778.7M
- Shares outstanding
- 63,067,485
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q1 FY 2026 | 2026-03-31 | $3.6M | -$53.5M | -1502.9% | -0.85 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$37.1M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$80.5M | n/a | -1.38 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$37.7M | n/a | -0.69 |
| Q1 FY 2025 | 2025-03-31 | $1.6M | -$43.6M | -2784.7% | -0.82 |
| Q4 FY 2024derived | 2024-12-31 | n/a | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$44.4M | n/a | -0.91 |
| Q2 FY 2024 | 2024-06-30 | n/a | -$56.3M | n/a | -1.16 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$199.0M | -$178.0M | $439K | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | -$239.6M | -$182.7M | $3.4M | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$308.5M | -$145.9M | $7.2M | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$126.8M | -$145.1M | $17.7M | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | $329.6M | $288.0M | $17.4M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-03-31; shares outstanding as of 2026-05-01 from the cover page.
What this page is
uniQure in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows uniQure (QURE), SEC CIK 1590560, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-10.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-07-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-03-31.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-29.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-02.JSON and CSV
- Company record
- EDGAR filing index for CIK 1590560Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUnited Therapeutics
- CPIXCumberland Pharmaceuticals
- REGNRegeneron Pharmaceuticals
- LLYEli Lilly
- VRTXVertex Pharmaceuticals
- ALNYAlnylam Pharmaceuticals
- CYTKCytokinetics
- BMYBristol Myers Squibb
- PTCTPTC Therapeutics
- INSMInsmed
- MDGLMadrigal Pharmaceuticals
- CORTCorcept Therapeutics
- IONSIonis Pharmaceuticals
- SDGRSchrodinger
- ROIVRoivant Sciences
- JNJJohnson & Johnson
- OPKOpko Health
- ALKSAlkermes
- ABBVAbbVie
- ABTAbbott Laboratories
- KNSAKiniksa Pharmaceuticals International
- BBIOBridgeBio Pharma
- ZTSZoetis
- JAZZJazz Pharmaceuticals
Datasets
Frequently Asked Questions
How much of QURE is sold short?
8,715,837 shares were held short at the 2026-09-30 settlement, 1.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is QURE's daily short volume?
On 2026-10-09, 150,609 of the 338,963 QURE shares reported to FINRA were sold short, 44.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does QURE have fails to deliver?
The SEC's latest file shows 52,675 QURE shares failed to deliver at settlement 2026-09-10. Fails are reported per settlement date and published twice a month with a lag.
Are QURE insiders buying or selling?
No open-market insider trades were reported for QURE in the last 90 days. The most recent filings are listed below. Latest filing: Kapusta Matthew C (CEO, Managing Director) on 2026-07-02.
Have QURE insiders filed to sell?
37 Form 144 notices on file for QURE worth $32.2M at the prices reported; 0 in the last 90 days worth $0. Latest: Kapusta Matthew C filed on 2026-07-02 to sell 21,082 shares ($952K) from 2026-07-02.
Who owns 5% or more of QURE?
5 holders report 5% or more of QURE in their latest filing, all on Schedule 13G (passive). The largest reported stake is Avoro Capital Advisors LLC at 9.9% of the class (6,150,000 shares), filed 2026-02-17 for an event on 2025-12-31.
What did QURE report last quarter?
In Q1 FY 2026 (quarter ended 2026-03-31) uniQure reported revenue of $3.6M, up 127.3% from the same quarter a year earlier, and net loss of $53.5M (-0.85 diluted EPS). In FY 2025 it generated -$178.0M of operating cash flow. As of 2026-03-31, cash was $140.0M against $49.9M of debt.
Which tracked 13F managers own QURE?
6 of the 30 tracked 13F managers held QURE shares at their latest filing, $164.5M in all. The largest: Two Sigma Investments (1.5M shares, $67.3M), Ken Griffin's Citadel Advisors (910K shares, $41.9M), Steve Cohen's Point72 Asset Management (606K shares, $27.9M), Izzy Englander's Millennium Management (343K shares, $15.8M), D. E. Shaw & Co. (208K shares, $9.6M), Cliff Asness's AQR Capital Management (43K shares, $2.0M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.